You are here

  • Home
  • Archive
  • Volume 35, Issue 3
  • A Double-Blind, Controlled, Randomized Trial to Evaluate the Efficacy of Botulinum Toxin for the Treatment of Lumbar Myofascial Pain in Humans

Article Text

Article menu
Download PDFPDF
ORIGINAL ARTICLES
A Double-Blind, Controlled, Randomized Trial to Evaluate the Efficacy of Botulinum Toxin for the Treatment of Lumbar Myofascial Pain in Humans
  1. José De Andrés, MD, PhD, FIPP*,†,‡,
  2. Vicente Martorell Adsuara, MD§,
  3. Stefano Palmisani, MD∥,
  4. Vicente Villanueva, MD‡ and
  5. Maria Dolores López-Alarcón, MD‡
  1. From the *Valencia University Medical School;
  2. †Anesthesia Department and
  3. ‡Multidisciplinary Pain Management Center, Valencia University GeneralHospital; and
  4. §Centro de Salud Picassent, Valencia, Spain; and
  5. ∥Departmentof Anesthesia, Critical Care and Pain Therapy, La Sapienza University of Rome, Rome, Italy.
  1. Address correspondence to: José De Andrés, MD, PhD, FIPP, Department ofAnesthesia, Critical Care and Pain Management, Hospital General Universitario, Avda Tres Cruces, s/n, 46014 Valencia, Spain (e-mail: deandres_jos{at}gva.es).

Abstract

Background: Among all the causes of chronic low back pain, myofascial pain syndrome of the spinal stabilizer muscles is one of the most frequent, yet underconsidered sources of pain. The purpose of this prospective, randomized, double-blind, controlled trial was to evaluate the efficacy of type-A botulinum toxin (BTX-A) in relieving myofascial pain in patients experiencing mechanical low back pain due to bilateral myofascial pain syndrome involving the iliopsoas and/or the quadratus lumborum muscles.

Methods: Each of the 27 enrolled patients received a bilateral, fluoroscopically guided injection in the affected muscle(s) to randomly deliver BTX-A in one side of the low back and a control drug (randomly constituted by NaCl 0.9% or bupivacaine 0.25%) in the opposite side. To evaluate the effects of treatment on daily life activities and psychologic status, 5 different questionnaires were administered (Hospital Anxiety and Depression scale [HAD-A and HAD-D], Lattinen, Oswestry, and Spielberger State-Trait Anxiety Index).

Results: BTX-A injection did not significantly reduce visual analog scale scores more than treatment with NaCl or bupivacaine in the contralateral side; furthermore, the treatments administered did not result in a significant improvement of patients' daily life activities or psychologic status. Although a trend toward a decrease in postintervention visual analog scale scores could be recognized in all low back sides, this trend was significant only in the sides treated with BTX-A.

Conclusions: BTX-A seems to provide significant postintervention pain relief. However, considering its high cost and the small differences compared with control treatments, its use should be reserved only for patients with pain refractory to other invasive treatments.

https://doi.org/10.1097/AAP.0b013e3181d23241

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.